Replimune Group, Inc.
↗Woburn, USA
Replimune Group, Inc. is a clinical-stage biotechnology company focused on the development of a novel class of oncolytic immunotherapies. The company utilizes its proprietary RPx platform, based on an engineered herpes simplex virus type 1 (HSV-1) backbone, to design therapies that induce direct tumor cell lysis while simultaneously stimulating a systemic anti-tumor immune response.
Headquartered in Woburn, Massachusetts, Replimune aims to establish its oncolytic immunotherapies as a cornerstone of cancer treatment, either as monotherapy or in combination with other immuno-oncology agents, such as checkpoint inhibitors. The company is currently focused on advancing its lead candidate, RP1, through clinical development and regulatory review for advanced melanoma and other solid tumors.
CLASSIFICATION
SIZE & FINANCIALS
Employees:51-200
Revenue:$0M
Founded:2015
Ownership:public
Status:operating
FUNDING
Stage:Post-IPO
Total Raised:$87M
Investors:Foresite Capital
STOCK
Exchange:NASDAQ
Ticker:REPL
Market Cap:$0.62B
PIPELINE
Stage:Phase 3
Lead Drug Stage:Phase 3
Modalities:Oncolytic virus
Active Trials:16
Trial Phases:Phase 3: 1
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Subsidiaries:Replimune Inc., Replimune Limited
Key Partnerships:Bristol-Myers Squibb (clinical collaboration for RP1/nivolumab), Regeneron, Incyte
COMPETITION
Position:Emerging
Competitors:Jazz Pharmaceuticals, Sana Biotechnology, Kite Pharma
LEADERSHIP
Key Executives:
Sushil Patel - CEO
Robert Coffin - Founder, President and Chief R&D Officer
Philip Astley-Sparke - Executive Chairman
Scientific Founders:Philip Astley-Sparke, Robert Coffin, Colin Love
Board Members:Dieter Weinand, Kapil Dhingra, Hyam Levitsky, Tanya Lewis, Paolo Pucci
LINKS
Website:replimune.com
LinkedIn:LinkedIn Profile
⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of Replimune Group, Inc. and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Replimune Group, Inc.. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.